

Cathrin Rohleder

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4099778/publications.pdf>

Version: 2024-02-01

41
papers

1,157
citations

430754

18
h-index

395590

33
g-index

46
all docs

46
docs citations

46
times ranked

1997
citing authors

#	ARTICLE	IF	CITATIONS
1	Simultaneous Assessment of Serum Levels and Pharmacologic Effects of Cannabinoids on Endocannabinoids and <i>N</i> -Acylethanolamines by Liquid Chromatography-Tandem Mass Spectrometry. <i>Cannabis and Cannabinoid Research</i> , 2023, 8, 657-669.	1.5	5
2	Identifying pathways to early-onset metabolic dysfunction, insulin resistance and inflammation in young adult inpatients with emerging affective and major mood disorders. <i>Microbial Biotechnology</i> , 2022, 16, 1121-1129.	0.9	6
3	Editorial: Immune Associated Mental Illnesses in Adolescents and Young Adults: Pathophysiological Role and Therapeutic Perspectives. <i>Frontiers in Psychiatry</i> , 2022, 13, 871719.	1.3	0
4	Protocol for a young adult mental health (Uspace) cohort: personalising multidimensional care in young people admitted to hospital. <i>BMJ Open</i> , 2021, 11, e038787.	0.8	1
5	Neural Autoantibodies in Cerebrospinal Fluid and Serum in Clinical High Risk for Psychosis, First-Episode Psychosis, and Healthy Volunteers. <i>Frontiers in Psychiatry</i> , 2021, 12, 654602.	1.3	19
6	Cannabidiol and Amisulpride Improve Cognition in Acute Schizophrenia in an Explorative, Double-Blind, Active-Controlled, Randomized Clinical Trial. <i>Frontiers in Pharmacology</i> , 2021, 12, 614811.	1.6	24
7	Case Report: Severe Adolescent Major Depressive Syndrome Turns Out to Be an Unusual Case of Anti-NMDA Receptor Encephalitis. <i>Frontiers in Psychiatry</i> , 2021, 12, 679996.	1.3	5
8	Neurobiology Youth Follow-up Study: protocol to establish a longitudinal and prospective research database using multimodal assessments for current and past mental health treatment-seeking young people within an early intervention service. <i>BMJ Open</i> , 2021, 11, e044731.	0.8	1
9	Supporting Clinicians to Use Technology to Deliver Highly Personalized and Measurement-Based Mental Health Care to Young People: Protocol for an Evaluation Study. <i>JMIR Research Protocols</i> , 2021, 10, e24697.	0.5	2
10	Psilocybin targets a common molecular mechanism for cognitive impairment and increased craving in alcoholism. <i>Science Advances</i> , 2021, 7, eabh2399.	4.7	39
11	Different pharmaceutical preparations of Δ^9 -tetrahydrocannabinol differentially affect its behavioral effects in rats. <i>Addiction Biology</i> , 2020, 25, e12745.	1.4	9
12	Cannabinoids and the endocannabinoid system in anxiety, depression, and dysregulation of emotion in humans. <i>Current Opinion in Psychiatry</i> , 2020, 33, 20-42.	3.1	42
13	Chronic Psychosocial Stress Causes Increased Anxiety-Like Behavior and Alters Endocannabinoid Levels in the Brain of C57BL/6 Mice. <i>Cannabis and Cannabinoid Research</i> , 2020, 5, 51-61.	1.5	10
14	Effects of Cannabidiol and Delta-9-Tetrahydrocannabinol on Emotion, Cognition, and Attention: A Double-Blind, Placebo-Controlled, Randomized Experimental Trial in Healthy Volunteers. <i>Frontiers in Psychiatry</i> , 2020, 11, 576877.	1.3	20
15	Youth Mental Health Tracker: protocol to establish a longitudinal cohort and research database for young people attending Australian mental health services. <i>BMJ Open</i> , 2020, 10, e035379.	0.8	5
16	Positron-Emission-Tomography Imaging of Long-Term Expression of the 18kDa Translocator Protein After Sudden Cardiac Arrest in Rats. <i>Shock</i> , 2020, Publish Ahead of Print, 620-629.	1.0	4
17	Right care, first time: a highly personalised and measurement-based care model to manage youth mental health. <i>Medical Journal of Australia</i> , 2019, 211, S3-S46.	0.8	88
18	Neural correlates of binocular depth inversion illusion in antipsychotic-naïve first-episode schizophrenia patients. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2019, 269, 897-910.	1.8	2

#	ARTICLE	IF	CITATIONS
19	Familial abnormalities of endocannabinoid signaling in schizophrenia. <i>World Journal of Biological Psychiatry</i> , 2019, 20, 117-125.	1.3	26
20	Role of the Endocannabinoid System in the Pathophysiology of Schizophrenia: Implications for Pharmacological Intervention. <i>CNS Drugs</i> , 2018, 32, 605-619.	2.7	36
21	Probing the endocannabinoid system in healthy volunteers: Cannabidiol alters fronto-striatal resting-state connectivity. <i>European Neuropsychopharmacology</i> , 2018, 28, 841-849.	0.3	41
22	570. Differential Association of Anandamide Levels with Binocular Depth Inversion Illusion Scores in Schizophrenia. <i>Biological Psychiatry</i> , 2017, 81, S230-S231.	0.7	0
23	Association of anandamide with altered binocular depth inversion illusion in schizophrenia. <i>World Journal of Biological Psychiatry</i> , 2017, 18, 483-488.	1.3	22
24	Putative Role of Endocannabinoids in Schizophrenia. , 2017, , 83-113.		0
25	Motor impairment and compensation in a hemiparkinsonian rat model: correlation between dopamine depletion severity, cerebral metabolism and gait patterns. <i>EJNMMI Research</i> , 2017, 7, 68.	1.1	14
26	PT600. Oylethanolamide Modulates Human Neural Responses to Food Stimuli in Obesity. <i>International Journal of Neuropsychopharmacology</i> , 2016, 19, 20-21.	1.0	0
27	The Functional Networks of Prepulse Inhibition: Neuronal Connectivity Analysis Based on FDG-PET in Awake and Unrestrained Rats. <i>Frontiers in Behavioral Neuroscience</i> , 2016, 10, 148.	1.0	47
28	Cannabidiol as a Potential New Type of an Antipsychotic. A Critical Review of the Evidence. <i>Frontiers in Pharmacology</i> , 2016, 7, 422.	1.6	75
29	Differential melatonin alterations in cerebrospinal fluid and serum of patients with major depressive disorder and bipolar disorder. <i>Comprehensive Psychiatry</i> , 2016, 68, 34-39.	1.5	42
30	What is the promise of nicotinic compounds in schizophrenia treatment?. <i>Future Medicinal Chemistry</i> , 2016, 8, 2009-2012.	1.1	3
31	Therapeutic Potential of Cannabinoids in Psychosis. <i>Biological Psychiatry</i> , 2016, 79, 604-612.	0.7	73
32	Cannabinoids and schizophrenia. , 2015, , 193-204.		1
33	IgG dynamics of dietary antigens point to cerebrospinal fluid barrier or flow dysfunction in first-episode schizophrenia. <i>Brain, Behavior, and Immunity</i> , 2015, 44, 148-158.	2.0	48
34	Identifying Gene-Environment Interactions in Schizophrenia: Contemporary Challenges for Integrated, Large-scale Investigations. <i>Schizophrenia Bulletin</i> , 2014, 40, 729-736.	2.3	229
35	Sleep deprivation in humans: Effects on melatonin in cerebrospinal fluid and serum. <i>Sleep and Biological Rhythms</i> , 2014, 12, 69-72.	0.5	7
36	Oleylethanolamide and Human Neural Responses to Food Stimuli in Obesity. <i>JAMA Psychiatry</i> , 2014, 71, 1254.	6.0	31

#	ARTICLE	IF	CITATIONS
37	Fatty acid ethanolamide levels are altered in borderline personality and complex posttraumatic stress disorders. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2014, 264, 459-463.	1.8	66
38	Inflammatory Molecular Signature Associated With Infectious Agents in Psychosis. <i>Schizophrenia Bulletin</i> , 2014, 40, 963-972.	2.3	88
39	Neural correlates of sensorimotor gating: a metabolic positron emission tomography study in awake rats. <i>Frontiers in Behavioral Neuroscience</i> , 2014, 8, 178.	1.0	21
40	A TWIN STUDY ON ABNORMALITIES OF ENDOCANNABINOID FUNCTIONING IN SCHIZOPHRENIA AND BIPOLAR DISORDER. <i>Schizophrenia Research</i> , 2012, 136, S26-S27.	1.1	0
41	Current State of Fluid Lipid Biomarkers for Personalized Diagnostics and Therapeutics in Schizophrenia Spectrum Disorders and Related Psychoses: A Narrative Review. <i>Frontiers in Psychiatry</i> , 0, 13, .	1.3	1